Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 known ✓ | Q99720 | 1/20 | 0.43 |
| ▸ | NAAA | Q02083 | 3/20 | 0.44 |
| ▸ | EPHX1 | P07099 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
| ▸ | EGFR | P00533 | 1/20 | 0.39 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.39 |
| ▸ | CNR1 | P21554 | 1/20 | 0.38 |
| ▸ | CNR2 | P34972 | 1/20 | 0.38 |
| ▸ | KCNH3 | Q9ULD8 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL7189275 | 1.00 | NAAA (0.44) | NAAASIGMAR1EPHX1ALDH1A1HTT | |
| Bromide SCHEMBL28143827 | 1.00 | NAAA (0.44) | NAAASIGMAR1EPHX1ALDH1A1HTT | |
| Bromide SCHEMBL28029812 | 1.00 | NAAA (0.44) | NAAASIGMAR1EPHX1ALDH1A1HTT | |
| Bromide SCHEMBL29054347 | 1.00 | NAAA (0.44) | NAAASIGMAR1EPHX1ALDH1A1HTT | |
| Bromide SCHEMBL10799774 | 1.00 | NAAA (0.44) | NAAASIGMAR1EPHX1ALDH1A1HTT | |
| Bromide SCHEMBL28289435 | 1.00 | NAAA (0.44) | NAAASIGMAR1EPHX1ALDH1A1HTT | |
| Bromide SCHEMBL28303675 | 1.00 | NAAA (0.44) | NAAASIGMAR1EPHX1ALDH1A1HTT | |
| SCHEMBL483594 | 0.98 | NAAA (0.45) | NAAASIGMAR1EPHX1ALDH1A1HTT | |
| SCHEMBL525869 | 0.98 | NAAA (0.45) | NAAASIGMAR1EPHX1ALDH1A1HTT | |
| SCHEMBL3170588 | 0.98 | NAAA (0.45) | NAAASIGMAR1EPHX1ALDH1A1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250262234-A1 | BISPHOSPHOCIN GEL FORMULATIONS AND USES THEREOF | Lakewood Amedex, Inc. | 2025-08-21 | — | — | US | disclosed |
| US-12156883-B2 | Bisphosphocin gel formulations and uses thereof | Lakewood Amedex, Inc. (US) | 2024-12-03 | — | — | US | disclosed |
| EP-3638251-B1 | BISPHOSPHOCIN GEL FORMULATIONS AND USES THEREOF | LAKEWOOD AMEDEX INC (US) | 2024-03-06 | — | — | EP | disclosed |
| EP-4241769-A2 | BISPHOSPHOCIN GEL FORMULATIONS AND USES THEREOF | Lakewood Amedex, Inc. (US) | 2023-09-13 | — | — | EP | disclosed |
| US-20230125677-A1 | BISPHOSPHOCIN GEL FORMULATIONS AND USES THEREOF | LAKEWOOD AMEDEX INC (US) | 2023-04-27 | — | — | US | disclosed |
| US-20210361689-A1 | BISPHOSPHOCIN GEL FORMULATIONS AND USES THEREOF | Lakewood Amedex, Inc. | 2021-11-25 | — | — | US | disclosed |
| US-20200360415-A1 | BISPHOSPHOCIN GEL FORMULATIONS AND USES THEREOF | Lakewood Amedex, Inc. | 2020-11-19 | — | — | US | disclosed |
| EP-3638251-A1 | BISPHOSPHOCIN GEL FORMULATIONS AND USES THEREOF | Lakewood Amedex, Inc. (US) | 2020-04-22 | — | — | EP | disclosed |
| WO-2018231863-A1 | BISPHOSPHOCIN GEL FORMULATIONS AND USES THEREOF | LAKEWOOD AMEDEX, INC (US) | 2018-12-20 | — | — | WO | disclosed |
| US-20180353529-A1 | BISPHOSPHOCIN GEL FORMULATIONS AND USES THEREOF | Lakewood Amedex, Inc. | 2018-12-13 | — | — | US | disclosed |
| US-20050107344-A1 | Antimicrobial compounds and methods for their use | OLIGOS ETC. INC. | 2005-05-19 | — | — | US | disclosed |
| EP-1389909-A4 | ANTIMICROBIAL COMPOUNDS AND METHODS FOR THEIR USE | OLIGOS ETC INC (US) | 2005-03-30 | — | — | EP | disclosed |
| EP-1389909-A1 | ANTIMICROBIAL COMPOUNDS AND METHODS FOR THEIR USE | Oligos Etc. Inc. (US) | 2004-02-25 | — | — | EP | disclosed |
| WO-2002089581-A1 | ANTIMICROBIAL COMPOUNDS AND METHODS FOR THEIR USE | OLIGOS ETC. INC. (US) | 2002-11-14 | — | — | WO | disclosed |
| US-20020032164-A1 | Antimicrobial compounds and methods for their use | LAKEWOOD-AMEDEX, INC. | 2002-03-14 | — | — | US | disclosed |
| EP-1140965-A1 | PROTONATED/ACIDIFIED NUCLEIC ACIDS AND METHODS OF USE | Oligos Etc. Inc. (US) | 2001-10-10 | — | — | EP | disclosed |
| EP-1140966-A1 | ACID STABLE BACKBONE MODIFIED END-BLOCKED NUCLEIC ACIDS AND THERAPEUTIC USES THEREOF | Oligos Etc. Inc. (US) | 2001-10-10 | — | — | EP | disclosed |
| WO-2000040592-A1 | ACID STABLE BACKBONE MODIFIED END-BLOCKED NUCLEIC ACIDS AND THERAPEUTIC USES THEREOF | OLIGOS ETC. INC. (US) | 2000-07-13 | — | — | WO | disclosed |
| WO-2000040591-A1 | PROTONATED/ACIDIFIED NUCLEIC ACIDS AND METHODS OF USE | OLIGOS ETC. INC. (US) | 2000-07-13 | — | — | WO | disclosed |
| US-5030659-A | Containing quaternary ammonium compound, oligo biguanidine hydrochloride and para phenylphenol | HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (DE) | 1991-07-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210361689-A1 | BISPHOSPHOCIN GEL FORMULATIONS AND USES THEREOF | BPGM, PPIP5K2, SOST | SIGMAR1 3438/4885NAAA 1237/4885EPHX1 2667/4885 |
| US-12156883-B2 | Bisphosphocin gel formulations and uses thereof | BPGM, PPIP5K2, SOST | SIGMAR1 3438/4885NAAA 1237/4885EPHX1 2667/4885 |
| US-20200360415-A1 | BISPHOSPHOCIN GEL FORMULATIONS AND USES THEREOF | BPGM, PPIP5K2, SOST | SIGMAR1 3438/4885NAAA 1237/4885EPHX1 2667/4885 |
| US-20180353529-A1 | BISPHOSPHOCIN GEL FORMULATIONS AND USES THEREOF | BPGM, PPIP5K2, SOST | SIGMAR1 3438/4885NAAA 1237/4885EPHX1 2667/4885 |
| US-20020032164-A1 | Antimicrobial compounds and methods for their use | ERG28, SLC11A2, NHERF1 | SIGMAR1 1675/4885NAAA 31/4885EPHX1 3544/4885 |
| US-20250262234-A1 | BISPHOSPHOCIN GEL FORMULATIONS AND USES THEREOF | BPGM, PPIP5K2, SOST | SIGMAR1 3438/4885NAAA 1237/4885EPHX1 2667/4885 |
| US-20050107344-A1 | Antimicrobial compounds and methods for their use | ERG28, SLC11A2, NHERF1 | SIGMAR1 1675/4885NAAA 31/4885EPHX1 3544/4885 |
| US-20230125677-A1 | BISPHOSPHOCIN GEL FORMULATIONS AND USES THEREOF | BPGM, PPIP5K2, SOST | SIGMAR1 3438/4885NAAA 1237/4885EPHX1 2667/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.